Clicky

  • Login
  • Register
  • Submit Your Content
  • Contact Us
Friday, August 23, 2024
World Tribune
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
Submit
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food
No Result
View All Result
World Tribune
No Result
View All Result

Novo Nordisk hits $500 billion in market value as it flags soaring demand for Wegovy, Ozempic

January 31, 2024
in News
Reading Time: 4 mins read
A A
Novo Nordisk hits 0 billion in market value as it flags soaring demand for Wegovy, Ozempic
0
SHARES
ShareShareShareShareShare

READ ALSO

Trump DJT stock could be sold within weeks

Nestle CEO replacement not such a bad thing for investors: Analyst

Liselotte Sabroe | Afp | Getty Images

Novo Nordisk on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar.

The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates to 232.3 billion kroner ($33.71 billion).

Full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner.

The Danish pharmaceutical giant said it expects sales growth this year of between 18% and 26% in CER terms, as demand surges for Wegovy and Ozempic, which contain the same active ingredient.

Novo Nordisk’s valuation rose to $506 billion at 08:06 GMT, according to CNBC’s calculation of LSEG data. The share price moderated slightly through the session, and was up by 1.3% on the day at 1:05 p.m. London time.

Novo remains Europe’s largest company by market capitalization, ahead of LVMH, which was valued at $422 billion ahead of Wednesday’s market open.

Novo Nordisk hits 0 billion in market value as it flags soaring demand for Wegovy, Ozempic

The 2023 results were fueled by strong performance in the company’s diabetes and obesity care division, with obesity care in particular spiking by 154% at CER to 41.6 billion kroner.

“We actually expect the same level of demand in the new year and when you look at the fact that we are only serving a couple of million patients living with obesity, some 40 million people living with diabetes — there is a huge market out there,” CEO Lars Fruergaard Jørgensen told CNBC on Wednesday.

Competition in the weight loss race has emerged for Novo Nordisk in the form of U.S. stalwart Eli Lilly. The Danish company has acknowledged this is likely to bring downward price pressures in the U.S., although Jørgensen said the competition would ultimately benefit patients.

“If you’re really going to make a big dent in treating people with obesity and preventing some of the follow-on diseases from that, it actually takes more than one company to do that, so I welcome competition that will help establish the obesity market,” he told CNBC’s Charlotte Reed on Wednesday.

“We’re used to competing on having the best products, and the incoming competitor we have been competing with for over 100 years — we have huge respect for each other — so that’s the healthy competition that actually brings better and better care to patients and takes the burden off health-care societies. So I think it’s a win-win for not only the two companies, but also for society.”

How soaring demand for Ozempic and Wegovy have led to Novo Nordisk's meteoric rise

While prices may have to come down, Novo Nordisk does not see a slowdown in global demand.

“The unmet needs in type 2 diabetes and obesity are growing by the day, and the rising prevalence of these closely related threats to global health has created surging demand for our GLP-1-based therapies,” Jørgensen and Chairman Helge Lund said in Wednesday’s earnings report.

“This has enabled us to reach more patients than at any point in our 100-year history, contributing to strong sales growth across North America and International Operations.”

The company also acknowledged that this had resulted in increased pressure on its supply chain, leading to “periodic constraints” across its portfolio as it struggled to keep pace with demand in 2023.

Pharma could see a wave of M&A activity in 2024, says Jefferies' Michael Yee

“We have responded by investing heavily in expanding our production capacity with the aim of serving millions more patients worldwide. In 2023 alone, we announced investments totalling more than DKK 75 billion in the expansion of our production sites across the globe,” the chairman and CEO said.

“With construction now underway on these projects, we strive to operate our existing facilities 24 hours a day, seven days a week, as we produce more of our life-changing medicines than ever before.”

Novo Nordisk said it had now begun to gradually increase supply of lower dosage Wegovy in the U.S., having restricted supply of the starter dose strength since last May.

Credit: Source link

ShareTweetSendSharePin
Previous Post

Travis Kelce details ‘cool moment’ seeing Taylor Swift celebrate Chiefs win

Next Post

From magic mushrooms to ayahuasca—psychedelics are the new leadership retreat

Related Posts

Trump DJT stock could be sold within weeks
News

Trump DJT stock could be sold within weeks

August 23, 2024
Nestle CEO replacement not such a bad thing for investors: Analyst
News

Nestle CEO replacement not such a bad thing for investors: Analyst

August 23, 2024
Japan’s yen has seen wild swings this year — is it still a safe-haven asset?
News

Japan’s yen has seen wild swings this year — is it still a safe-haven asset?

August 23, 2024
Canadian rail lockout leaves billions in U.S. trade stranded
News

Canadian rail lockout leaves billions in U.S. trade stranded

August 23, 2024
A robot that gives massages — this is what it looks and feels like
News

A robot that gives massages — this is what it looks and feels like

August 23, 2024
July home sales break 4-month losing streak as supply rises nearly 20%
News

July home sales break 4-month losing streak as supply rises nearly 20%

August 22, 2024
Next Post
From magic mushrooms to ayahuasca—psychedelics are the new leadership retreat

From magic mushrooms to ayahuasca—psychedelics are the new leadership retreat

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

What's New Here!

Microsoft Recall AI search for Windows Insiders releases in October

Microsoft Recall AI search for Windows Insiders releases in October

August 21, 2024
Japan trade on deck, Wall Street rally pauses

Japan trade on deck, Wall Street rally pauses

August 21, 2024
Q&A: Google on creating the loss of pulse detection technology

Q&A: Google on creating the loss of pulse detection technology

August 16, 2024
Starbucks welcomes new CEO Brian Niccol with a 3 million payday—and he can work remotely

Starbucks welcomes new CEO Brian Niccol with a $113 million payday—and he can work remotely

August 15, 2024
Two of our favorite Ooni pizza ovens are deeply discounted right now

Two of our favorite Ooni pizza ovens are deeply discounted right now

August 8, 2024
Meta advertising growth proof that hefty AI spending is paying off

Meta advertising growth proof that hefty AI spending is paying off

August 1, 2024
How Japan’s yen could be ripping through U.S. stocks

How Japan’s yen could be ripping through U.S. stocks

August 2, 2024

About

World Tribune is an online news portal that shares the latest news on world, business, health, tech, sports, and related topics.

Follow us

Recent Posts

  • Jazz Chisholm back in Yankees lineup after being activated from IL
  • MAUI emerges from stealth with $4M Department of Defense contract
  • Jerome Powell signals ‘the time has come’ to cut U.S. interest rates in September
  • Five Trends Worth Watching in the Edible Oils Market

Newslatter

Loading
  • Submit Your Content
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • DMCA

© 2024 World Tribune - All Rights Reserved!

No Result
View All Result
  • Home
  • News
  • Business
  • Technology
  • Sports
  • Health
  • Food

© 2024 World Tribune - All Rights Reserved!

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In